ERNAHealthcare · BiotechnologyThe 1 Wall Street analysts covering Ernexa Therapeutics, Inc. hold a median 12-month price target of $30 — +596.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 5 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Ernexa Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (94): Smaller than most of the companies we track.
Value (15): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ERNA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +596.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 May 2026 | Brookline Capital | Initiates | Buy | $30 |
| 14 Dec 2022 | Morgan Stanley | Maintains | Equal-Weight | — |
| 12 Dec 2022 | B of A Securities | Upgrade | Buy | — |
| 14 Nov 2022 | Needham | Maintains | Buy | — |
| 10 Aug 2022 | Needham | Maintains | Buy | — |
| 15 July 2022 | Morgan Stanley | Maintains | Equal-Weight | — |
| 12 May 2022 | JP Morgan | Upgrade | Overweight | — |
| 11 May 2022 | Needham | Maintains | Buy | — |
| 2 Mar 2022 | Needham | Maintains | Buy | — |
| 11 Nov 2021 | Needham | Maintains | Buy | — |
| 1 Oct 2021 | Needham | Maintains | Buy | — |
| 16 June 2021 | Morgan Stanley | Maintains | Equal-Weight | — |
| 13 May 2021 | Needham | Maintains | Buy | — |
| 21 Apr 2021 | JP Morgan | Initiates | Neutral | — |
| 19 Apr 2021 | Needham | Maintains | Buy | — |
| 26 Mar 2021 | Morgan Stanley | Initiates | Equal-Weight | — |
| 25 Mar 2021 | Needham | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ERNA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Sept 2026, Ernexa Therapeutics, Inc. returned −85.9% against +20.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 74% of US stocks
Cheaper than 55% of US stocks
Cheaper than 62% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 5% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Ernexa Therapeutics, Inc. has a market value of $5.0M and an enterprise value of $2.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$12.3M.
Free cash flow in the twelve months to 30 June 2026: −$8.9M.
Trailing P/E: 0.0×; forward P/E: −0.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Ernexa Therapeutics, Inc. employs 5 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Ernexa Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Ernexa Therapeutics participated in the Virtual Investor "Why Now" on-demand conference, and a video webcast of the event is now available for viewing.
Why it matters — The conference provides investors and industry watchers with an opportunity to hear Ernexa's management present the company's current positioning and strategy in an on-demand format.
Ernexa Therapeutics has appointed David Polinsky, a veteran biotech executive with over 25 years of experience in oncology, capital markets, M&A, and corporate governance, to its board of directors as the company approaches the clinical stage.
Why it matters — The addition of a seasoned biotech founder and CFO to the board signals strengthened leadership and governance experience as Ernexa prepares to transition into a clinical-stage company.
Ernexa Therapeutics' CEO discussed the future of combination cancer therapies and explained how the company's drug candidate, ERNA-101, was designed to convert immunologically "cold" tumors into targets for the immune system.
Why it matters — An ERNA watcher would care because the CEO's comments highlight ERNA-101's potential role in combination cancer therapy, which could broaden its clinical applicability beyond standalone use.
The 1 Wall Street analysts covering Ernexa Therapeutics, Inc. have a median 12-month price target of $30, with estimates ranging from $30 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Ernexa Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ernexa Therapeutics, Inc. 38 out of 100 across roughly 4,600 US stocks as at 5 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 5 Sept 2026, Ernexa Therapeutics, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +596.1% from the last close, and Ticker Nerd's factor model ranks Ernexa Therapeutics, Inc. 38 out of 100 as at 5 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Ernexa Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ERNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $30 over the next 12 months.
Ernexa Therapeutics, Inc. returned -85.9% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Ernexa Therapeutics Inc. is a biotechnology company focused on developing cell-based therapies for advanced cancer and autoimmune diseases.
The most recent item we track (GlobeNewsWire, 27 Aug 2026): "Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference". Ernexa Therapeutics participated in the Virtual Investor "Why Now" on-demand conference, and a video webcast of the event is now available for viewing.
Ernexa Therapeutics Inc. is a biotechnology company focused on developing cell-based therapies for advanced cancer and autoimmune diseases. The company’s current programs center on engineered induced pluripotent stem cells and induced mesenchymal stem cells designed to create off-the-shelf, allogeneic treatments that can be manufactured without patient-specific cell harvesting. Its pipeline includes preclinical product candidates aimed at ovarian cancer and rheumatoid arthritis, reflecting its emphasis on therapeutic areas with high unmet medical need. Ernexa Therapeutics Inc. works at the intersection of cell engineering, immunology, and regenerative medicine, using proprietary mRNA and gene-modification technologies to direct how cells behave and deliver targeted biological effects. Headquartered in Cambridge, Massachusetts, the company operates as a clinical-stage biotechnology developer with a focused role in the evolving market for next-generation cellular medicines.
CEO Mr. Sanjeev Luther · 5 employees · United States · https://www.ernexatx.com
